Read about the latest insights in skin cancer care with a new whitepaper on advanced basal cell carcinoma and advanced cutaneous squamous cell carcinoma. View the complimentary resource today!
A recent study published in JAMA Dermatology shed light on the often-discordant perceptions of disease severity in patients with eczema and psoriasis when compared to their physicians.
A recent study published in JAMA Dermatology shed light on the often-discordant perceptions of disease severity in patients with eczema and psoriasis when compared to their physicians.
Jarad Levin, MD; Katelin Harrell, MD; Kelsey Johnson, MS
In this article, we present a patient with a history of recalcitrant HHD who had clearance of her current disease flare with the topical JAK inhibitor ruxolitinib.
In this article, we present a patient with a history of recalcitrant HHD who had clearance of her current disease flare with the topical JAK inhibitor ruxolitinib.
In this roundtable session, expert dermatologists describe current diagnostic approaches and risk factors for disease progression in advanced cutaneous squamous cell carcinoma (aCSCC) and advanced basal cell carcinoma (aBCC). This discussion...
In this roundtable session, expert dermatologists describe current diagnostic approaches and risk factors for disease progression in advanced cutaneous squamous cell carcinoma (aCSCC) and advanced basal cell carcinoma (aBCC). This discussion...
Which of the following clinical features is most strongly associated with an increased risk of developing psoriatic arthritis in patients with psoriasis?
Which of the following clinical features is most strongly associated with an increased risk of developing psoriatic arthritis in patients with psoriasis?
Clinicians vary in when they escalate to JAK inhibitor therapy for alopecia areata. Take the quiz to see if your threshold aligns with current expert consensus.
Clinicians vary in when they escalate to JAK inhibitor therapy for alopecia areata. Take the quiz to see if your threshold aligns with current expert consensus.
Older patients need special consideration. Take the quiz to identify which systemic drug class carries higher risks—like thrombosis and malignancy—and requires extra caution in aging populations.
Older patients need special consideration. Take the quiz to identify which systemic drug class carries higher risks—like thrombosis and malignancy—and requires extra caution in aging populations.
Explore the ethical flaws in labeling alopecia areata as a cosmetic concern. Take the quiz to uncover the strongest rationale for reclassifying AA as a medical condition.
Explore the ethical flaws in labeling alopecia areata as a cosmetic concern. Take the quiz to uncover the strongest rationale for reclassifying AA as a medical condition.